ERASCA INC
NASDAQ: ERAS (Erasca, Inc.)
Last update: 3 hours ago14.05
0.04 (0.29%)
| Previous Close | 14.01 |
| Open | 14.15 |
| Volume | 2,078,145 |
| Avg. Volume (3M) | 6,875,512 |
| Market Cap | 4,369,332,736 |
| Price / Book | 11.10 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.570 |
| Total Debt/Equity (MRQ) | 12.72% |
| Current Ratio (MRQ) | 12.35 |
| Operating Cash Flow (TTM) | -107.72 M |
| Levered Free Cash Flow (TTM) | -91.89 M |
| Return on Assets (TTM) | -22.16% |
| Return on Equity (TTM) | -45.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Erasca, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.69% |
| % Held by Institutions | 84.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Mar 2026 | 24,675,188 |
| Vivo Capital, Llc | 31 Mar 2026 | 12,151,480 |
| Siren, L.L.C. | 31 Mar 2026 | 11,244,246 |
| Arch Venture Management, Llc | 31 Mar 2026 | 7,091,557 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |